Human Cytomegalovirus Cytoplasmic Virion Assembly Complex: Structure In Vivo And Role Of Pul103 In Its Biogenesis by Lim, Ma Christina Raye
Wayne State University
Wayne State University Theses
1-1-2017
Human Cytomegalovirus Cytoplasmic Virion
Assembly Complex: Structure In Vivo And Role
Of Pul103 In Its Biogenesis
Ma Christina Raye Lim
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_theses
Part of the Molecular Biology Commons, and the Virology Commons
This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Theses by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Lim, Ma Christina Raye, "Human Cytomegalovirus Cytoplasmic Virion Assembly Complex: Structure In Vivo And Role Of Pul103 In
Its Biogenesis" (2017). Wayne State University Theses. 575.
https://digitalcommons.wayne.edu/oa_theses/575
HUMAN CYTOMEGALOVIRUS CYTOPLASMIC VIRION ASSEMBLY COMPLEX:  
STRUCTURE IN VIVO AND ROLE OF pUL103 IN ITS BIOGENESIS 
by 
MA CHRISTINA RAYE LIM 
THESIS 
Submitted to the Graduate School 
of Wayne State University, 
Detroit, Michigan 
in partial fulfillment of the requirements 
for the degree of 
MASTER OF SCIENCE 
2017 
       
            MAJOR:  IMMUNOLOGY AND  
                                MICROBIOLOGY 
              Approved By: 
                  _________________________________________  
                   Advisor                  Date 
TABLE OF CONTENTS 
List of Tables.…………………………………………………………………………..…………ii 
List of Figures.………………………………………………………………………………..…..iii 
Chapter 1 General Background.……………………………………………………………..…….1 
Chapter 2 Detecting the cVAC structure in vivo……………………………………..…….…..…8 
 Introduction……………………………………………………………………………..…8 
 Materials and Methods…………………………………………………………..…….….8 
 Results……………………………………………………………………………………10 
 Discussion………………………………………………………………………………..11 
Chapter 3 Role of pUL103 in cVAC biogenesis…………………………………………………22 
 Introduction………………………………………………………………………………22 
 Materials and Methods…………………………………………………………..…….…23 
 Results……………………………………………………………………………………23 
 Discussion………………………………………………………………………………..23 
Chapter 4 Conclusions.…………………………………………………………………..………27 
References.……………………………………………………………………………………….28 
Abstract…………………………………………………………………………………………..30 
Autobiographical Statement…………………………………………………..…………………31 
i
LIST OF TABLES 
Table 1: List of buffers used……………………………………………………………………..15 
Table 2: Experimental conditions………………………………………………………………..16 
Table 3: Primary antibodies used in immunofluorescence assay.………………………………..17 
Table 4:  Effect of pUL103 on cVAC biogenesis in the presence or absence of Shield-1 ligand..26 
ii
LIST OF FIGURES 
Figure 1: Pancreas H&E stain showing Owl’s eye morphology of an infected cell……….……..7 
Figure 2: HCMV induces cytopathic effects in host cells forming the cVAC.……………..……13 
Figure 3: Control slides that show staining of the corresponding antibodies……………………14 
Figure 4: Placenta tissue infected with HCMV.………………………………………………….18 
Figure 5: Tissue slides that show positive viral nuclear and cytoplasmic staining………………19 
Figure 6: Colon tissue infected with HCMV…………………………………………………….20 
Figure 7: Three dimensional aspects of an HCMV infected cell...………………………………21 
Figure 8: Regulatable Shield-1 ligand protects a protein of interest from proteasomal degradation 
……………………………………………………………………………………………………24 
Figure 9: Experimental design to study the effect of pUL103 on the formation of cVAC using a       
    regulatable Shield-1 ligand added at different time points…………………………….25 
iii
 1
CHAPTER 1  GENERAL BACKGROUND 
Human Cytomegalovirus 
 Epidemiology.  Human cytomegalovirus (HCMV) is one of the many members of the 
Herpesviridae.  It is a worldwide opportunistic pathogen typically acquired early in life.  It is 
estimated that 40-100% of the population have HCMV antibody present in their blood. 
Seroprevalence increases with age and approximately 85% of adults over the age of 70 is HCMV 
seropositive (1).  Other factors associated with increased seroprevalence include ethnicity, 
socioeconomic status, and living in crowded conditions.  Primary infections are asymptomatic in 
majority of cases.  However, immunocompromised patients are at higher risk for serious 
manifestations as well as recurrence.  Illness may manifest as an influenza-like illness to severe 
disease with multi-system organ failure or dysfunction.  The protracted effects alone of HCMV 
disease on these high-risk populations warrants a development of improve treatment and 
prevention of this viral infection. 
 HCMV is transmitted from person to person through a variety of ways which include 
contact with infected body fluids including saliva, tears, breast milk, urine, and genital 
secretions.  Seroconversion has been documented between family members and individuals in 
day care centers where unhygienic habits of children make it easy to transmit the virus; 
prolonged viral shedding is common in children (2).  Sexual activity plays a role in acquiring 
HCMV infection.  Since the virus is present in genital secretions, having multiple sexual partners 
or a history of high-risk sexual activity increases the likelihood of infection.  The virus can also 
be excreted asymptomatically, thus, frequent shedding in saliva and urogenital secretions enable 
asymptomatic transmission of the virus (2). 
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 HCMV is one of the TORCH microbes: a group of microbes that can cross the placenta 
(Toxoplasma gondii, (Other), rubella, HCMV, herpes simplex virus 1 and 2).  Fetuses have a high 
risk of acquiring HCMV disease in utero during primary maternal infection.  Also, it can be 
acquired perinatally from exposure to birth canal secretions during delivery, or postnatally from 
maternal milk during breast feeding.  
 In addition, HCMV can also be transmitted via blood products and tissue and organ 
transplants. 
 Like all members of the Herpesviridae, HCMV exhibits latency that can reactivate 
periodically especially when the host becomes immunosuppressed.  HCMV establishes latency 
in the progenitors of the myeloid lineage, mainly the monocyte precursors (3).  HCMV 
replication occurs widely in multiple tissues, including neutrophils, leukocytes, and monocytes, 
which can serve as vehicles for spread (4).  Due to its broad tissue tropism, it can cause a wide 
spectrum of disease.   
 Clinical disease.  Most adults possess HCMV antibodies and are normally 
asymptomatic.  A self-limiting febrile illness is a common presentation during primary infection. 
Symptomatic infection may present as mononucleosis (also known as heterophile antibody 
negative mononucleosis to distinguish from that caused by Epstein-Barr virus.)  Mononucleosis 
characterized by fever, chills, sweats, headache and pharyngitis is more commonly observed in 
young adults.  Skin rashes such as macular, papular, or rubelliform spots may accompany these 
signs and symptoms (3).  Common lab anomalies will be atypical lymphocytes, 
thrombocytopenia, elevated rheumatoid factor and anemia.  In some cases, elevated atypical 
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lymphocytes and liver enzymes could persist for many months.  A post-viral fatigue syndrome 
can occur in some adults (5). 
 For the immunocompromised host, the primary HCMV infection replicates 
uncontrollably and can lead to disseminated infections.  HCMV infection in 
immunocompromised hosts can have different clinical manifestations depending on the 
population.  Seropositive bone marrow transplant patients, or those receiving a positive donor 
bone marrow, have a high risk of developing severe HCMV pneumonitis that can lead to death. 
The presentation of pneumonitis is presumed to be a pathological consequence from the host 
immune response against the virus (3).  AIDS patients commonly develop viremia, progressive 
retinitis that may lead to blindness, and diarrhea from HCMV colitis.  Further, HCMV can 
disseminate to the brain causing encephalitis (3). 
 HCMV colitis is uncommon in immunocompetent people.  However in the 
immunocompromised host, it can lead to fulminating colitis manifesting as severe bloody 
diarrhea, abdominal pain, and fevers.  Diagnosis requires a high degree of clinical suspicion and 
a biopsy is generally needed in almost all cases (6). 
 Other clinical syndromes described with HCMV is pericarditis and myocarditis.  Post 
HCMV Guillain-Barré syndrome is a well described but uncommon sequela following resolution 
of infection (5). 
 Congenital HCMV.  HCMV is the most common cause of congenital infections, about 
1% of live births, and approximately 10 percent of those are symptomatic at birth (7).  If due to 
primary maternal infection, the fetus is more likely to be symptomatic at birth or experience 
long-term sequelae which can include progressive hearing loss, visual and intellectual 
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impairment, severe disease including organ damage, CNS abnormalities, or death.  Disease 
manifestation is most severe if primary infection was acquired during the first trimester of fetal 
development.  Sensorineural hearing loss (SNHL) is the most common sequelae of congenital 
disease caused by viral spread into the inner ear structures forming a focus of infection 
accompanied by inflammation.  Other signs and symptoms include thrombocytopenia purpura, 
hepatitis, pneumonitis and myocarditis (3).   
 HCMV infection in the elderly.  In immunocompetent adults, illness is generally self 
limiting.  It is one of the viral illness which can present as fever of unknown origin lasting for 
more than 4-6 weeks with absence of lab anomalies.  In such cases, diagnosis is difficult and 
other infections, malignancies and cancers have to be ruled out (8). 
 Lab Diagnosis.  HCMV can be detected in a variety of specimens: tissue, urine, 
respiratory secretions, CSF, peripheral blood, and other body fluids.  However, since most of us 
can shed this virus asymptomatically, diagnosis of symptomatic infection is best confirmed by 
detection of HCMV DNA from sterile body fluids (e.g., peripheral blood and its components, 
CSF.)  PCR method is the gold standard for testing owing to its high sensitivity and faster turn 
around time compared to cell cultures.  False positive can occur and interpretation of PCR results 
should correlate with clinical symptoms, and in some cases, an H&E tissue biopsy confirmation 
may be necessary (9). 
 Other methods available include detection of IgG or IgM antibodies by serology (e.g., 
ELISA), detection of HCMV pp65 antigen in leukocytes, growth in human fibroblast cell 
cultures, and histopathology.  In histopathology slides, HCMV exhibits a characteristic “Owl’s 
eye” intranuclear inclusions in a cytomegalic infected cell (Fig. 1), although this feature may be 
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absent in some infected organs.  Biopsies may be performed if organ involvement is suspected, 
or in cases of disseminated infections. 
 Diagnosis of congenital HCMV can be done in utero by amniocentesis if the infection is 
suspected due to primary maternal infection or from abnormal findings on the ultrasound.  The 
sensitivity of this sample depends on the timing of collection: there is higher sensitivity if 
collected after 21 weeks of gestation and a 6 weeks lag time between maternal infection and 
collection that takes into account replication of the virus in the placenta, transmission to the fetus 
and consequent replication in the fetal kidney and excretion into the amniotic fluid (10).  The 
amniotic fluid is then tested for the presence of HCMV DNA using PCR.   
 For perinatal diagnosis, the standard method is a PCR test on saliva collected within 3 
weeks of birth.   This is followed by a urine test for confirmation.  The saliva must be collected 
at least 1 hour after breast feeding because HCMV-positive mothers can shed HCMV in their 
breast milk and may cause a false positive result on the saliva sample collected soon after breast 
feeding (10). 
 Molecular.  HCMV is a betaherpesvirus with an enveloped virion that houses a linear 
double-stranded DNA.  At approximately 230 kbp, it is the largest genome among the human 
herpesviruses.  Primary attachment for entry requires the viral glycoproteins gB, gH, and gL that 
attach to the heparan sulfate proteoglycan receptors on the host cells.  The virus may either enter 
a lytic cycle, or go latent.  The lytic replication cycle has three phases beginning with the 
expression of the immediate early genes that code for regulatory proteins, early genes that code 
for proteins used for replication, and the late genes that regulate the structural proteins to make 
complete virions.  The permissiveness of a cell for the lytic cycle or the pathogenesis of an 
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HCMV infection involves complex interactions between the virus and its host.  The large HCMV 
genome encodes genes that allow the virus to counteract many host defenses.  
  Treatment and Prevention.   Cell-mediated immunity is the primary immune response 
required to control HCMV infection, which explains why the high-risk groups for severe disease 
are those who have deficiencies in CD4+ and CD8+ lymphocytes.  Common antiviral drugs used 
against HCMV (i.e., foscarnet, valganciclovir, ganciclovir) are highly toxic and are only used to 
treat high risk groups such as those with congenital disease and infections in 
immunocompromised hosts.  No vaccines are currently available.  Preventative measures to 
curtail the risk of transmission include good hand washing/proper hygienic practices, and using 
seronegative donor blood or tissue products (11).  A deeper understanding of the effects of 
HCMV and the mechanism of its pathogenicity on infected cells is vital to the development of 
vaccines and new antiviral drugs that are less toxic. 
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FIG 1 Pancreas H&E stain showing Owl’s eye morphology (arrow) of an infected cell. 40X 
cropped.  Tissue slide from Detroit Children’s Hospital.
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CHAPTER 2 DETECTING THE cVAC STRUCTURE IN VIVO 
Introduction 
 HCMV induces cytopathic effects in host cells typically characterized by an enlarged 
kidney-bean shaped nucleus bent around a Golgi ring with the endosomes at the center forming 
the structure known as the cytoplasmic virion assembly complex (cVAC) (Fig. 2).  The cVAC is 
where virus particles are assembled and trafficked out of the cell.  This structure has been 
elucidated and demonstrated in vitro in multiple studies (12-14), however, no in vivo studies 
have been done.  Cellular markers that detect the cVAC structure include the Golgi, trans-Golgi, 
and early endosomes.  We aim to detect by immunofluorescence assay some of the cellular and 
viral components that form the cVAC to learn if the formation of this complex can be observed in 
vivo.   
Materials and Methods 
 Materials.  12 sets of formalin-fixed, paraffin-embedded tissue slides from children with 
congenital HCMV were obtained from Detroit Children’s Hospital courtesy of Dr. Janet Poulik, 
M.D., Department of Pathology, Detroit Medical Center, with Institutional Review Board (IRB) 
approval.  Dr. Noman Hussain (Fellow in Infectious Diseases) was instrumental in getting the 
approval from the IRB and helped during the process of developing the experimental methods.   
 The tissue slides were taken from various infected anatomical sites: lung, colon, stomach, 
intestines, trachea, etc., and the quantity of infected cells in each set were assessed using a 
Hematoxylin & Eosin (H&E) stained slide.  Slides that exhibit more than 2 infected cells per 
40X field were used for the experiment.  In addition to the slides from congenitally infected 
children, commercially prepared placenta (Azer Scientific) and lung (StatLab) tissue slides were 
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also used in the early phase of the experiment.  Commercially prepared CMV infected control 
slides (Bion, Inc) were used to verify the functionality of the antibodies in each experiment (Fig. 
3) 
 Deparaffinization, rehydration, and antigen retrieval.  Based on preliminary 
experiments, the optimized protocol described in this section was used.   
 Paraffin used to solidify the tissue sections for slicing must be removed first prior to 
staining to allow buffers and antibodies to penetrate.  This was done by baking the slides at 50℃ 
for 1 hour to melt the paraffin wax followed by three xylene washes at 5 minutes each.  Next, 
xylene was removed with two 100% ethanol washes, then the tissue slides were hydrated 
gradually through 95% and 70% alcohol washes and two washes with distilled water.  The 
formalin fixative used to preserve the integrity of the tissue sections induces the formation of 
methylene bridges between proteins that may potentially block antigenic sites.  Heating the slides 
can cleave these cross-links between proteins (15).  This was accomplished with a heat-induced 
antigen retrieval (HIER) method by immersing the slides in a buffer jar inside an 80-90 ℃ water 
bath.  As the heating and subsequent cooling process cause folding and re-folding of the 
polypeptides, masked epitopes are exposed.  The re-folding of the polypeptide chains can be 
affected by the buffer pH which determines how the positive- and negatively-charged 
polypeptides react with each other (15).  We made our own buffers using Abcam’s 
recommendations (16).  In addition, we used R-Universal Epitope Recovery Buffer (Electron 
Microscopy Sciences).  As shown in Tables 1 and 2, we tried different duration and temperature 
of baking and antigen retrieval, and explored different buffers to optimize the deparaffinization, 
rehydration, and antigen-retrieval steps for our tissue slides.   
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 Immunofluorescent staining.  After the HIER step, the slides were washed with PBS 
and autofluorescence was quenched by incubation in 50 mM ammonium chloride for 30 minutes. 
This was followed by permeabilization in blocking serum with 0.2% Triton-X for 25 minutes, 
incubation in blocking serum only for 1 hour, then stained with primary antibodies overnight at 
4℃ (antibodies described in Table 3).  The slides were then stained with fluorescent-tagged 
secondary antibodies for 1 hour at room temperature (Alexa Fluor 488-conjugated goat anti-
mouse IgG and Alexa Fluor 568-conjugated goat anti-rabbit IgG, both from Molecular Probes, 
Carlsbad, CA).  The slides were mounted with Vectashield containing DAPI (4’, 6-diamidino-2-
phenylindole) (Vector Laboratories Inc., CA).  Imaging was done on a Nikon E800 fluorescence 
microscope.   As shown in Table 2, variations in the duration of incubation were performed to 
specifically optimize the staining procedure for our slides. 
Results 
 The ability to visualize cellular structures varied with the quality of the slides and the 
staining process performed.  Initial efforts included identification of the optimal procedure to 
clear the paraffin from the different types of tissue slides, detecting the epitopes of interest, and 
quenching the autofluorescence typically observed in tissue sections.  Once we developed the 
optimum experimental procedure by trying different combinations of the factors shown in Tables 
1 and 2, (optimal protocol is as described in the Deparaffinization…, and Immunofluorescent 
staining sections above), we were able to detect good nuclear IE2 staining in most of the slides 
(Figs. 4 and 5).  Other viral proteins tested such as glycoprotein B (gB) and pp28 were also 
detected (Figs. 5A, 5B) which proved the ability of the procedure to detect HCMV infected cells. 
As expected, the tissue sections with more infected cells per field (i.e., colon, ovary, pancreas) 
 11
provided better results.  Fig. 6 shows a classic kidney-bean shaped infected colon cell with 
staining of the Golgi and early endosomes evident in the area of the cVAC.   
 Staining of the Golgi and early endosomes, structures classically associated with the 
cVAC, were not consistently evident in every slide tested.  This could be attributed to the three-
dimensional nature of the tissue sections which affects the orientation of the infected cell seen 
microscopically; an example is shown on Fig. 7 (12).   
Discussion 
 The objective of this work was to detect the cVAC structure in FFPE tissue slides.  By 
developing an optimized staining procedure, we discovered that the cVAC is formed in tissue 
specimens.   
 An important aspect to keep in mind when working with tissue slides as opposed to a 
monolayer of cells grown in culture is the three dimensional aspect of the specimen.  As the 
FFPE section is sliced, the structures of interest could be severed and exhibit a shape or form that 
is not consistent with their typical morphology.  Also, the angle of the cell on the tissue could 
hide expected features.  Fig. 6 from our experiment suggests that the cVAC is indeed present in 
tissue as it is in cell cultures.  More robust evidence is needed however, and would require a 
more extensive and three-dimensional microscopic study of ideally-positioned infected cells in 
tissue sections.  A limitation of this study was the amount of acceptable slides available for 
testing.  A majority of the slides contained rare to very few scattered infected cells and were not 
ideal for testing.  Interesting to note, this “scattered infection” seems to be a feature consistent 
with how HCMV establishes an infection.  Mayer et al. recently reported that HCMV spreads to 
neighboring cells inefficiently and normally requires numerous tries to establish an infection 
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(17).  This phenomenon can be observed on Fig. 1 which shows 2 infected cells in the center 
surrounded by many uninfected cells.   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HCMV in HLF cells 5 dpi
Uninfected HLF
DAPI (Nucleus)  
GM130 (Golgi) 
EEA1 (Early/recycling endosomes)
FIG 2 HCMV induces cytopathic effects in host cells forming the cVAC.  Das and Pellett, J. Virol. 2011.FIG 2 HCMV induces cytopathic effects in host cells forming the cVAC.  (Left) Uninfected 
HLF cell (human lung fibroblast) with the Golgi adjacent to the nuclei and the early endosomes 
scattered around the cell.  (Right)  Infected cell 5 dpi (days post infection) showing an enlarged 
bent nucleus with the Golgi forming a ring structure and the endosomes localized in the center. 
Das and Pellett, J. Virol. 2011.
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DAPI (Nucleus)  
IE2 (Nucleus), GM130 (Golgi) 
EEA1 (Early/recycling endosomes)
FIG 3 Control slides showing staining of the corresponding antibodies.  (A) Negative control 
well.  (B) Positive control well.
A BNegative Positive
FIG 3 Commercial fibroblast control slides that show staining of the corresponding antibodies. 
(A) Negative control with cells staining for the cellular markers GM130 and EEA1.  (B) 
Positive control showing the classic large kidney-bean shaped nucleus on top right staining 
with the viral nuclear marker IE2, and the cellular Golgi and EEA1 markers localized in the 
center, as expected.  
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Sodium citrate pH 6.0 EDTA pH 8.0 Tris base pH 9.0 R-Universal
10 mM sodium citrate, 0.05% Tween 20, 
pH 6.0 
Abcam recipe: 
     2.94 g Tri-sodium citrate (dihydrate) 
dissolved in 1 L of deionized water.  pH 
adjusted to 6.0 with 1N HCl.  0.5 ml 
Tween 20 added.   
1 mM EDTA, pH 8.0 
Abcam recipe: 
     0.37 g EDTA dissolved in 1 L of 
deionized water.  pH adjusted to 8.0 
with NaOH
10 mM Tris base, 1 mM EDTA solution, 
0.05% Tween 20, pH 9.0  
Abcam recipe: 
     1.21 g of Tris and 0.37 g of EDTA             
dissolved in 1 L of deionized water.  pH 
adjusted to 9.0 with NaOH.  0.5 ml 
Tween 20 added.
R-Universal Epitope Recovery Buffer 
(Electron Microscopy Sciences)
Step Variations
Bake slides
not performed 
50-55 ℃ for 1 hour
Heat-induced antigen retrieval incubation period
0 minutes 
20 minutes 
30 minutes 
1 hour
Heat-induced antigen retrieval water bath temperature 
60 ℃ 
85-90 ℃
Triton-X permeabilization step incubation period 0 minutes 
15 minutes 
25 minutes
Blocking step duration with 50 mM ammonium chloride 0 minutes 
15 minutes 
30 minutes
Primary antibody incubation period 1 hour in room temperature; antibody diluted in 
blocking buffer only 
1 hour in room temperature; antibody diluted in 
blocking buffer with Triton-X 
Overnight incubation at 4 ℃; antibody diluted 
in blocking buffer only
Secondary antibody incubation period 1 hour in room temperature
TABLE 1 Buffer Type and pH
TABLE 2 Experimental conditionsT  2  Experimental conditions
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Antibody Target Host/Isotype, clone Source, catalog no.
Epitope tag
V5 (14 amino acids) Mouse monoclonal/IgG2aκ LifeTechnologies, R960-25
Cellular
GM130 (130kDa) Mouse monoclonal/IgG1(κ), clone 35/GM130 BD Biosciences, 610822
EEA1 (180kDa) Rabbit polyclonal Abcam, ab2900
Mann II Rabbit polyclonal Abcam, ab12277
HCMV
IE2 (86kDa) Mouse monoclonal, clone 8B1.2 Chemicon (Millipore), MAB810
pUL99 (pp28) Mouse monoclonal/IgG2A(k), 5C3 Virusys, CA004-100 
gB (55 kDa and 110 kDa) Mouse monoclonal/ IgG1(k), clone 2F12 Virusys, CA005-100 
TABLE 3 Primary antibodies used in Immunofluorescence assay
TABLE 3  Primary antibodies used in immunofluorescence assay
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FIG 4 Placenta   Nuclei  IE2 (Nucleus)  GM130 (Golgi)  EEA1
FITC
TexRed Merge
DAPI
FIG 4 Placenta tissue infected with HCMV.  IE2 staining is evident in the infected cells, 
however, the Golgi and early endosomes are not detected in this slide.  Infected cells may not 
exhibit the typical kidney-bean shaped nucleus but are cytomegalic.  
DAPI (Nucleus)  
IE2 (Nucleus), GM130 (Golgi) 
EEA1 (Early/recycling endosomes)
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FIG 5 Tissue slides that show positive viral nuclear and cytoplasmic staining.  (A) Ovary 
tissue.  Arrows pointing at gB cytoplasmic staining of an infected cell.  (B) Placenta tissue. 
Arrow pointing at pp28 cytoplasmic staining of an infected cell.
DAPI (Nucleus)  
IE2 (Nucleus) 
gB (envelope protein, cytoplasmic)
DAPI (Nucleus)  
IE2 (Nucleus)  
pp28 (tegument protein, cytoplasmic)
A B
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FIG 5 Colon    Nuclei  IE2 (Nucleus)  GM130 (Golgi)  EEA1
FITCDAPI
TexRed Merge
DAPI (Nucleus)  
IE2 (Nucleus), GM130 (Golgi) 
EEA1 (Early/recycling endosomes)
FIG 6 Colon tissue infected with HCMV.  Orientation of the tissue section showed the 
characteristic large kidney-bean shaped nucleus along with staining of the Golgi and early 
endosomes in the cVAC area.  
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FIG 7 Three dimensional aspects of an HCMV infected cell.  Image from Das et al 2007.
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CHAPTER 3 ROLE OF pUL103 IN cVAC BIOGENESIS 
Introduction 
 pUL103 is a tegument protein with known functions during the late replication cycle of 
HCMV.  Previous works in the Pellett laboratory have shown that pUL103 is involved in the 
cVAC biogenesis, cell-to-cell spread, and virion maturation and egress (18).  Contributors to the 
assembly of the cVAC can be potential targets for new antivirals and warrant further study.   
 Here we try to address the question of whether the presence of pUL103 at early times 
after infection is critical for cVAC biogenesis.  To study the effects of pUL103,  pUL103 was 
fused with a destabilization domain (FKBP) that can be regulated by the presence or absence of 
Shield-1 ligand.  Shield-1 ligand attachment to the pUL103 construct stabilizes and protects it 
from proteasomal degradation (Fig. 8) (19).  The experimental design shown in Fig. 9 anticipates 
that cVAC biogenesis occurs around 3 days post infection.  pUL103 is a late protein and is 
synthesized just prior to the cVAC, around 48 hours p.i., continuing throughout the course of the 
infection.  Previous siRNA knockdown experiments done in the Pellett lab have shown that less 
pUL103 is synthesized late in the infection (18) represented in Fig. 9 (pUL103 siRNA) with a 
thin bar compared to the wild type (pUL103 wt).  With our pUL103-FKBP construct (pUL103-
FS+), if Shield-1 is present, input pUL103 from infecting virions and newly made pUL103 
should be comparable to wild type levels.  However in the absence of Shield-1, input pUL103 is 
degraded more quickly, in addition, less are being synthesized.  The experimental design aims to 
determine whether the input pUL103 plays a role in the re-arranging of the cVAC area of an 
infected cell and if reducing this amount will have an effect on that process. 
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Materials and Methods 
 Human foreskin fibroblast (HFF) cells were seeded at 80% confluency on 0.2% gelatin-
coated 8-well glass chamber slides (Thermo Fisher Scientific, Waltham, MA).  The next day, the 
cells were infected with UL103-FKBP-V5 HCMV construct at 0.1 MOI and Shield-1 was added 
in certain chamber wells under set time points of 0 hpi and then at 12 hour increments as 
illustrated in Fig. 9.  Shield-1 was replenished every 2 days in the corresponding wells.  At 144 
hpi, the slides were fixed with paraformaldehyde and stained and imaged as previously described 
in Chapter 2.  The number of infected cells with fully formed cVAC were quantified relative to 
those without. 
Results 
 Table 4 shows the results of the 2 experiments.  In Experiment 1, 15% of infected cells 
have well-formed cVAC in the absence of Shield-1 compared to 37% when Shield-1 was present 
throughout the course of the experiment.  When Shield-1 was omitted until later time points, 
there was no defect in cVAC formation.   
 Experiment 2 differed from Experiment 1 in that it had more extended period prior to 
addition of Shield-1.  Experiment 2 has similar observations except that in the No Shield-1 added 
control the fraction of cells with well-formed cVAC was higher than in Experiment 1 (30% vs. 
15%), however, it was still lower than the other time points in the experiment. 
Discussion 
 The objective of these experiments is to elucidate the role of input pUL103 in cVAC 
biogenesis.  Our results indicate that it is not critical for pUL103 to be present at wild type levels 
during the early time of infection for cVAC biogenesis to occur.  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FIG 8 Regulatable Shield-1 ligand protects a protein of interest from proteasomal degradation. 
Hagan EL, et al.  2009. 
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CHAPTER 4  CONCLUSIONS 
 Human cytomegalovirus is a prevalent opportunistic pathogen that targets and cause 
severe disease to those who have a weakened immune system.  A hallmark characteristic of its 
effect on the host cell is enlargement of nuclei and subsequent remodeling of the internal 
structures to form the  cytoplasmic virion assembly complex (cVAC) in the center.   The cVAC is 
the final site of virion maturation and egress, and viral proteins involved in its biogenesis are 
potential targets for antivirals.  To further learn about the pathogenesis of HCMV infection we 
studied the structure of the cVAC in tissue slides from patients with congenital HCMV and 
discovered that cVAC forms in tissue similar to cell cultures.  Previous work in the Pellett 
laboratory had identified viral genes important in cVAC biogenesis, one of which is pUL103. 
pUL103 is a multi-functional tegument protein that plays many other roles in the pathogenesis of 
the infection.  To study its potential role during the early stages of cVAC biogenesis, we 
conducted time point studies using a pUL103-FKBP construct whose presence in the infection 
can be regulated with the addition of a Shield-1 ligand.  Our findings suggest that input pUL103 
at early stages of infection is not critical in the formation of cVAC at later times. 
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ABSTRACT 
HUMAN CYTOMEGALOVIRUS CYTOPLASMIC VIRION ASSEMBLY COMPLEX:  
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 Human Cytomegalovirus (HCMV) is a linear, double stranded DNA virus that causes 
severe disease in the immunocompromised, and is one of the common cause of congenital 
disease.  Antivirals that are currently available for treatment target the DNA replication of the 
virus cycle, and are highly toxic.  Finding new drug targets, such as proteins responsible for 
virion assembly and egress, would help to alleviate the disease burden.   
 HCMV remodels the host cell to form a structure called the cytoplasmic virion assembly 
complex (cVAC), a site of virion maturation and egress.  The first objective of this work is to 
study the structure of the cVAC in vivo by immunofluorescence assay using slides from children 
with congenital HCMV, and we discovered that the cVAC is also formed in vivo.  The second 
objective is to elucidate the role of pUL103 in cVAC biogenesis in the early stages of infection 
using a regulatable pUL103-FKBP construct and Shield-1 ligand.  We found that decreased 
levels of pUL103 at the early stages of infection is not critical for cVAC biogenesis at later times 
of the infection.  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